Quality Chemical Industries Limited (Qcil), Uganda’s leading pharmaceutical manufacturer, has announced a period of unprecedented growth, unveiling its financial results for the year ended March 31, 2025, and outlining an ambitious expansion plan set to significantly impact healthcare accessibility in Uganda and across Africa.
The announcement was made ahead of the company’s Annual General Meeting (AGM).
The pharmaceutical giant reported strong financial performance, highlighting stellar revenue of UShs 267.1 billion and an 18% increase in gross profit to a record UShs 108.4 billion. Net profit surged by 22% to a record UShs 40.7 billion, reflecting improved operational efficiency and disciplined financial management.
In recognition of this outstanding performance, the Board recommended and shareholders approved a final dividend of UShs 13.5 per share for FY2024/25, more than double last year’s total payout of UShs 5.7 per share, reaffirming Qcil’s commitment to delivering value to its shareholders.
“This strong performance reflects our operational focus and public health mission,” said Mr. Ajay Kumar Pal, CEO of Qcil. “Our success is a testament to our team’s dedication. We thank our shareholders, team, and partners for their continued trust as we build for the future.”
Investing in the Future: Expanding Capacity to Meet Africa’s Evolving Health Needs
Qcil’s ambitious plans extend beyond financial gains, with a significant strategic investment aimed at bolstering healthcare infrastructure.
Shareholders were briefed on Qcil’s next phase of growth, which includes a USD 36 million loan facility to construct a second manufacturing plant. This new facility will expand Qcil’s annual capacity to 2.4 billion tablets and introduce new lines for tuberculosis treatments, injectables, and other innovative products.
Qcil’s economic contributions and social impact continue to grow, with tax payments consistently rising, reaching UShs 19.8 billion in 2025 (UShs 15.1 billion in 2024).
Mr. Emmanuel Katongole, Chairman and co-founder of Qcil, emphasized the broader implications of these developments.
“Qcil’s impact goes beyond numbers; we are saving lives by ensuring consistent access to essential medicines,” he stated. “Our partnership with the government and international health organizations ensure these critical treatments reach those who need them most.”
Katongole further articulated the company’s vision, stating, “We are investing in Uganda’s health and prosperity.” He added, “This expansion will enable us to do more for our patients, our people, and our economy.”
A Pillar of Public Health: Combatting HIV and Malaria at Scale
Qcil remains a critical player in Uganda’s response to major public health challenges, including HIV and malaria. Qcil manufactures 1.4 billion tablets annually of its life-saving antiretroviral (ARVs) and antimalarial drugs, ensuring reliable and affordable access to essential medicines for millions.
Quality Chemical Industries Limited is a publicly listed Ugandan pharmaceutical company founded in 2005, and is dedicated to manufacturing quality, affordable medicines.
As Africa’s largest producer of WHO-prequalified malaria treatments, Qcil’s vision is to be a centre of excellence in the manufacturing of quality, affordable medicines.
